Abbott Xinlay "not approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott's selective endothelin-A receptor antagonist Xinlay (atrasentan) is "not approvable" Oct. 13 for metastatic, hormone refractory prostate cancer (HRPC). FDA's decision follows a unanimous recommendation against Xinlay approval by the agency's Oncologic Drugs Advisory Committee Sept. 13 (1Pharmaceutical Approvals Monthly October 2005, p. 3). Abbott's NDA is based on a post hoc meta-analysis of subgroups in two failed pivotal trials; the firm has suggested non-metastatic HRPC as a potential alternative pathway for Xinlay...
You may also be interested in...
Dendreon To File Provenge BLA In 2006 Based On Survival Data
Dendreon plans to submit a BLA for its prostate cancer vaccine Provenge in 2006 following FDA feedback suggesting that existing data is sufficient for filing, the firm says.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.